Xenon Pharmaceuticals Priced, Nasdaq: XENE
Licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne.
Industry: Health Care
First Day Return: +16.7%
XENE
Licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne.
| IPO Data | |
|---|---|
| IPO Date | 11/04/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $36 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Burnaby, Canada |
| Founded | 1996 |
| Employees at IPO | 74 |
| Website www.xenon-pharma.com | |
IPO News for Xenon Pharmaceuticals
Xenon Pharmaceuticals (XENE) Performance
